World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
30994
World Ranking
14958
National Ranking
7558

Anthony D. Elias publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anthony D. Elias sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 336 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anthony D. Elias D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anthony D. Elias sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anthony D. Elias is affiliated with the University of Colorado Boulder in the United States. Their research spans multiple areas within medicine and biological sciences, with a significant focus on oncology and related subfields.

The scientist's work primarily covers the following fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader categories, their subfields of study include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Elias's research topics concentrate heavily on cancer, particularly breast cancer. Main topics of work comprise:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Estrogen and related hormone effects

The scientist has contributed to high-impact research venues with frequent publications in:

  • Cancer Research (21 publications)
  • Journal of Clinical Oncology (19 publications)
  • Journal of the National Comprehensive Cancer Network (6 publications)
  • Clinical Cancer Research (5 publications)
  • npj Breast Cancer (5 publications)

Among recent papers authored or co-authored by Anthony D. Elias are:

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer, 2020, JAMA Oncology
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2023, 2023, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021, 2021, Journal of the National Comprehensive Cancer Network

Frequent collaborators in their research include:

  • Hope S. Rugo
  • Laura J. Esserman
  • Erica Stringer-Reasor
  • W. Fraser Symmans
  • Douglas Yee

Best Publications

  • Clinical practice guidelines in oncology

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    William J. Gradishar;Benjamin O. Anderson;Jame Abraham;Rebecca Aft

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression

    Karen S. Antman;James D. Griffin;Anthony Elias;Mark A. Socinski

  • GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN

    MarkA. Socinski;Anthony Elias;Lowell Schnipper;StephenA. Cannistra

  • Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

    Robert G. Maki;David R. D'Adamo;Mary L. Keohan;Michael Saulle

  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

    William D Tap;William D Tap;Robin L Jones;Robin L Jones;Brian A Van Tine;Bartosz Chmielowski

  • Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Harold J. Burstein;Anthony D. Elias;Hope S. Rugo;Melody A. Cobleigh

  • An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

    K Antman;J Crowley;S P Balcerzak;S E Rivkin

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

    Rita Nanda;Minetta C Liu;Christina Yau;Rebecca Shatsky

  • Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Hope S. Rugo;Olufunmilayo I. Olopade;Angela DeMichele;Christina Yau

  • A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

    K Antman;L Ayash;A Elias;C Wheeler

  • NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

    Paul G Richardson;Carol Murakami;Zhezhen Jin;Diane L Warren

  • Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

    Dawn R Cochrane;Sebastián Bernales;Britta M Jacobsen;Diana M Cittelly

  • Adaptive Randomization of Neratinib in Early Breast Cancer

    John W Park;Minetta C Liu;Douglas Yee;Christina Yau

  • Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

    AD Elias;L Ayash;KC Anderson;M Hunt

  • Invasive breast cancer version 1.2016

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.

    Anthony Elias;Louise Ryan;Aaron Sulkes;Jerry Collins

  • Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population

    Paul G. Richardson;Anthony D. Elias;Amrita Krishnan;Catherine Wheeler

Frequent Co-Authors

Karen H. Antman
Karen H. Antman Boston University
Virginia F. Borges
Virginia F. Borges University of Colorado Boulder
Jennifer K. Richer
Jennifer K. Richer University of Colorado Anschutz Medical Campus
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Judy C. Boughey
Judy C. Boughey Mayo Clinic
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Kathy S. Albain
Kathy S. Albain Loyola University Chicago
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Claudine Isaacs
Claudine Isaacs Georgetown University
Angela DeMichele
Angela DeMichele University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine opens doors to a wide range of advanced degrees and trajectories beyond the MD. For those interested in healthcare leadership, pursuing one of the top cahme-accredited mha programs can lead to roles in hospital management and administration. These online programs offer flexibility for working professionals who want to move into leadership positions.

Nurses seeking to advance their education may benefit from online rn to bsn programs without clinical requirements, which allow for degree completion without the need for on-site clinical hours. This is particularly appealing for working RNs balancing job commitments and family life.

For those striving to reach the highest levels of nursing practice, there are options such as short dnp programs that enable quicker completion, as well as a variety of dnp online programs designed for convenience and flexibility. These pathways can help medical professionals expand their scope of practice and pursue specialized or leadership positions in healthcare.

Best Scientists Citing Anthony D. Elias

Trending Scientists

Recently Published Articles